Top Markets
#1 Black Phoenix Black Phoenix +860.29%
#2 QuantixAI QuantixAI +102.63%
#3 MetaDAO MetaDAO +26.72%
#4 Pons Pons +23.08%
#5 LayerZero LayerZero +20.52%
#6 Ontology Gas Ontology Gas +19.80%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +19.11%
#8 Bedrock Bedrock +18.57%
#9 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +18.04%
#10 SPX6900 SPX6900 +15.41%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Clasificación en acciones #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Precio por acción
$43.48
Capitalización bursátil
$8.97B
Cambio (1 día)
0.37%
Cambio (1 año)
192.01%
País
US
Comercio Immunovant, Inc. (IMVT)

Categoría

Healthcare
Ingresos de Immunovant, Inc. (IMVT)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Immunovant, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Immunovant, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH